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Abstract
BACKGROUND: The golden Syrian hamster is an emerging model organism. To optimize its use, our group has made the first
genetically engineered hamsters. One of the first genes that we investigated is KCNQ1 which encodes for the KCNQ1 potassium
channel and also has been implicated as a tumor suppressor gene. MATERIALS AND METHODS: We generated KCNQ1
knockout (KO) hamsters by CRISPR/Cas9mediated gene targeting and investigated the effects of KCNQ1deficiency on
tumorigenesis. RESULTS: By 70 days of age seven of the eight homozygous KCNQ1 KOs used in this study began showing signs
of distress, and on necropsy six of the seven ill hamsters had visible cancers, including Tcell lymphomas, plasma cell tumors,
hemangiosarcomas, and suspect myeloid leukemias. CONCLUSIONS: None of the hamsters in our colony that were wildtype or
heterozygous for KCNQ1 mutations developed cancers indicating that the cancer phenotype is linked to KCNQ1deficiency. This
study is also the first evidence linking KCNQ1deficiency to blood cancers.
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The golden Syrian hamster (Mesocricetus auratus) is an emerging model organism for human diseases that complements current
rodent models. It has been demonstrated to be especially effective in modeling human disorders such as inflammatory myopathies,
emerging viral infectious diseases, Clostridium difficile infection, pancreatitis, dietinduced obesity, and early atherosclerosis, insulin
resistance, dyslipidemia, and virally and chemically induced cancers.[1],[2] However, until recently, a significant challenge for the
use of hamsters in modeling human diseases was the inability to generate genetically engineered hamsters. This barrier has
recently been surmounted, resulting in gene knockouts (KOs) and knockins in the hamster by employing CRISPR/Cas9mediated
gene targeting, PiggyBacmediated transgenesis, and pronuclear injection.[3],[4] This permitted the creation of the first genetic
models of cancer in hamsters. One of the first genes that we investigated encodes for the KCNQ1 potassium channel. KCNQ1 is
widely expressed in human and rodent tissues, including heart, skeletal muscle, smooth muscle, inner ear, renal proximal tubules,
gastric parietal cells, exocrine pancreas, intestinal epithelia, lung, hepatocytes, breast, bone marrow, thymic T cells, and white
blood cells.[5],[6],[7],[8],[9],[10],[11],[12],[13],[14] KCNQ1 protein expression data in humans from the human protein atlas[15]
indicates that KCNQ1 expression is considered high in thyroid, parathyroid and adrenal glands, in stomach and duodenum, and
seminal vesicles; medium in heart, cerebellum, bone marrow, skeletal and smooth muscle, lung, liver, pancreas, oral mucosa,
jejunum and ileum, colorectum, kidney, breast, skin, placenta, and uterus; and low in cerebral cortex, hippocampus, salivary
glands, esophagus, testis and ovary (www.proteinatlas.org). KCNQ1 can act as either an S4 domaincontaining voltagegated
potassium ion channel or as a constitutively active channel, depending on the identity of its KCNE subfamily heterodimeric partner.
[12],[16] KCNQ1 function is best known for its voltagegated interaction with its KCNE1 heterodimeric partner, such as in cardiac
myocyte repolarization.[12] In contrast, when KCNQ1 partners with KCNE3, as in the intestinal epithelium, KCNE3 locks open the
KCNQ1 S4 domain to remove the voltage dependence of KCNQ1 activation, converting it to a constitutively active K+ channel.[12]
The KCNQ1 gene is developmentally imprinted, with its expression controlled by a long noncoding RNA, KCNQ1ot1, that lies within
exon 10 of the KCNQ1 gene (and which is itself reciprocally imprinted).[17] A large number of novel enhancers at the KCNQ1 locus
are reported to regulate the expression of KCNQ1 in specific tissues[18] and Wnt/βcatenin signaling is implicated in the regulation
of both KCNQ1 and KCNQ1ot1.[19],[20],[21] KCNQ1 mutations cause a range of disease in humans such as cardiac arrhythmia
(Long QT syndrome), inner ear defects, and gastric hyperplasia.[22],[23] Germline mutations in humans are associated with
disorders called RomanoWard Syndrome and Jervell and LangeNielson Syndrome.[23] Notably, KCNQ1 has been shown to act
as a tumor suppressor in mouse and human gastrointestinal cancers.[24],[25],[26] In our current study, eight KCNQ1 homozygous
KO hamsters were aged and phenotyped. As early as 70 days of age, seven of these homozygous mutants started showing signs
of distress, and on necropsy six of the seven ill hamsters had aggressive visible cancers.

Materials and Methods

Creation of KCNQ1 knockout hamsters
The KCNQ1 gene was knocked out in hamsters by CRISPR/Cas9 gene targeting and pronuclear injection following a protocol
previously described.[3],[4] Briefly, a sgRNA/Cas9 gene targeting vector designed for hamster KCNQ1 was constructed using
thepX330U6Chimeric BBCBhhSpCas9 plasmid (Addgene ID: 42230).[27] The final construct was confirmed by Sanger
sequencing. The design of the KCNQ1 KO allele is depicted in [Figure 1]a. The 11 bp insertion abolishes a BglI restriction enzyme
site, thereby genotyping was carried out by a polymerase chain reactionrestriction fragment length polymorphism (PCRRFLP)
assay. PCR primers are listed in [Figure 1]b. To determine the success of the design, genotyping and targeting efficiency, gene
targeting was conducted in baby hamster kidney (BHK) cells. BHK fibroblasts (BHK; American Type Culture Collection, Manassas,
VA, USA) were cultured in Minimum Essential Medium supplemented with 10% fetal bovine serum, nonessential amino acids, and
PenicillinStreptomycin (Life Technologies, Carlsbad, CA, USA). A volume of 5 mg of circular sgRNA/Cas9 vectors were transfected
into 106 BHK cells using Amaxa 4DNucleofector (Program No. CA137; Lonza, Allendale, NJ, USA). Two days posttransfection,
cells were harvested for genomic DNA isolation using Puregene Core Kit A (Qiagen, Valencia, CA, USA) following the
manufacturer's protocol. Target DNA was PCR amplified from the genomic DNA isolated from BHK cells using Phusion Highfidelity
DNA polymerase (Thermo Scientific, Waltham, MA, USA), [Figure 1]c (left). After digestion with BglI, the PCR products were
resolved on a 1% agarose gel and stained with SYBR green dye (Life Technologies, Carlsbad, CA, USA) [Figure 1]c (right). To
determine gene targeting efficiency, the relative intensities of uncut band and cut bands were analyzed using the Image J software
(1.47p, NIH). To produce KCNQ1 KO hamsters, we microinjected the sgRNA/Cas9 gene targeting vector into the pronuclei of
hamster zygotes, followed by transferring the injected hamster embryos to recipient females and allowed the resultant pregnant
females to naturally deliver and raise the pups. Genotyping analysis of the F0 pups was done by PCRRFLP assays, and the
genotyping results for F0 pups are shown in [Figure 2]a. To reveal the nature of the indels introduced, genomic PCR products used
in the PCRRFLP assays for each of the pups were subcloned into TA cloning vectors and sequenced by Sanger sequencing. To
establish a KCNQ1 KO breeding colony, we bred F0F7 (female; carrying both + 1nt and + 11nt indels) with a WT male. Genotyping
analysis with the PCRRFLP assays showed that both the +1nt and + 11nt indels transmitted to the germline [Figure 2]b.
Genotyping results by the PCRRFLP assay on F2 pups produced sister–brother breeding between two heterozygous F1 pups (#6
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and #8) [Figure 2]c, both carrying the + 11nt allele, and produced three homozygous KO (#1, 2, and 3), 7 heterozygous KO (#4, 5,
8, 10, 11, 12, and 13) and four WT (#6, 7, 9, and 14) F2 pups [Figure 2]d. To identify potential offtargets, we did blast searches
with
the
sgRNA
coding
sequence
as
the
query
against
the
hamster
genome
(https://uswest.ensembl.org/Mesocricetus_auratus/Info/Index). Top potential offtargets for sgRNAs are listed in [Table 1]. The
corresponding DNA oligos for each of the targeting sites were synthesized by Integrated DNA Technologies (Coralville, Iowa, USA).
We performed PCRRFLP assays for each of these genomic loci but did not identify any offtargeting events. KCNQ1 homozygous
KO hamsters demonstrate similar neurological defects (unpublished data from our group) as KO mice,[25] including deafness,
inner ear defects, head bobbing, and smaller stature. For this reason, breeding required crosses between heterozygous animals.
Hamster histopathology on formalinfixed tissues was conducted by two trained pathologists at our institutions pathology core
facility. All animal work was approved by the Institutional Animal Care and Use Committees at our universities.{Figure 1}{Figure 2}
{Table 1}

Results

Cancers in KCNQ1 knockout hamsters
Seven of the eight homozygous mutants developed severe physical distress beginning at ~70 days of age, including six hamsters
with overt cancers at necropsy. The cancers were synchronous, often large and infiltrative to multiple organs – liver, lung, pancreas
and omentum, intestine, kidney, spleen, sternum, lymph nodes, and stomach in addition to systemic myeloproliferative disease
involving bone marrow, lung, liver, and spleen. The major cancers observed were Tcell lymphomas, plasma cell tumors, and
hemangiosarcomas (HAS). None of the 48 hamsters in our colony that were wildtype or heterozygous KO for KCNQ1 developed
cancers indicating that the cancer phenotype is linked to KCNQ1deficiency. Heterozygous animals were also generally
phenotypically normal. As shown in [Table 2], a detailed description of all hamsters including gross and microscopic pathology
findings and diagnoses.{Table 2}
Tcell lymphomas
Tcell lymphomas were the most common cancers observed in hamsters. Three hamsters were diagnosed with abdominal masses
and Tcell lymphoma involving liver, spleen, kidney, small intestine, colon, pancreas and omentum, based on histopathology and
antiCD3 immunohistochemistry [Figure 3].{Figure 3}
Plasma cell tumors
Plasma cell neoplasms, similar to multiple myeloma in humans, were diagnosed in two hamsters by histopathology and methyl
greenpyronin staining, and found in liver, pancreas, spleen, omentum, lymph nodes, and mesentery. In one hamster, a plasma cell
tumor mass measuring 4 cm × 3 cm × 3 cm engulfed the liver, pancreas, spleen, and associated lymph nodes and local mesentery.
A prominent lymphoid population (suspect lymphoma) was found coinfiltrating the plasma cell tumor in these animals. Plasma cells
were also found coinfiltrating tissues with Tcell lymphoma [Figure 4].{Figure 4}
Hemangiosarcoma
HSA, while a common cancer in canines,[28] is rare in humans and rodents. Based on pathology, we observed multifocal HSA in
the lungs and HSA and hemangiomas in the liver of two hamsters [Figure 5].{Figure 5}
Myeloid disease and other suspect cancers and findings
Myeloproliferative disease was observed in four animals (with possible myeloid leukemia in one animal) involving bone marrow,
lung, liver, and spleen; this involved multiple lineages, notably, the granulocytic series (heterophil, sometimes eosinophil), and in
addition plasma cells, megakaryocytes and red cells to varying degrees. In one hamster, a prominent myeloid/polymorphonuclear
population was observed in the bone marrow that was also infiltrating the adjacent fibrous connective tissue of the sternum and
striated muscle. One hamster was diagnosed with granulosa cell tumor involving the ovaries.

Discussion

To the best of our knowledge, this study represents the creation of the first genetically engineered hamster cancer model. Our work
is also the first evidence linking KCNQ1deficiency to blood cancers. How might KCNQ1deficiency cause blood cancers in
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hamsters? In humans and mice, KCNQ1 has been reported to be expressed in several types of hematopoietic cells, including
thymic T cells,[14] bone marrow (www.proteinatlas.org), and murine white blood cells,[13] although KCNQ1 expression patterns in
hamsters have not been fully characterized. There is also a report that disruption of KCNQ1 in mice results in an accumulation of
mature T cells.[14] One mechanistic possibility is that KCNQ1 may synergize with hamster polyomavirus (HaPV). HaPV is thought
to be endemic in hamster colonies worldwide (including ours), and an outbreak of lymphomas was reported in a colony in Spain of
the genetic audiogenic seizureprone hamster: Salamanca strain of hamsters susceptible to audiogenic seizures.[29] Notably,
studies of this colony have suggested that the seizure phenotype may be linked to a deficiency for the nonvoltagegated KCC2
potassium channel in the brain.[30] Thus, there is the possibility that a potassium channel deficiency may cooperate with HaPV in
cancer development. More specifically, deficiency for the voltagegated KCNQ1 potassium channel could cause membrane
depolarization in bone marrowderived stem cells, contributing to their transformation. A role for KCNQ1 in regulation of stem cell
transformation has been proposed for KCNQ1deficiency in gastrointestinal cancer, arising from bidirectional Wnt/βcatenin
signaling.[21] Consistent with this, in GI cancer KCNQ1 expression was linked to the regulation of intestinal stem cell mRNA in
mice,[25] and KCNQ1 protein expression has been localized to the intestinal stem cell compartment of intestinal crypts
(unpublished work by our group). Further support for a role in stem cells is a report of KCNQ1 expression in a murine bone marrow
derived pluripotent small embryonic/epiblastderived stem cell Very small embryoniclike stem cells.[31] Future studies will need to
analyze whether Wnt/βcatenin signaling is dysregulated in KCNQ1deficient bone marrowderived hamster progenitor cells,
especially with the emerging evidence of a major role for Wnt signaling in hematological malignancies.[32] Finally, the observation
of HAS in addition to neoplasia involving several hematopoietic cell lineages in these hamsters is interesting, and appears to be
consistent with the finding of this tumor in dogs and its attribution to transformation of a common progenitor hematopoietic cell.[28]
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